Cathie Wood’s ARK ETF published their daily trades for Thursday, April 4th, 2024, revealing a series of strategic moves in the tech and biotech sectors. The most significant trade of the day involved a sell-off of Coinbase Global Inc (NASDAQ:), with a total of 25,662 shares divested across ARKK and ARKW ETFs, amounting to $6,456,046.
In contrast, ARK displayed bullish sentiment on Roblox Corp (NYSE:RBLX), purchasing 59,883 shares spread across three of its funds—ARKK, ARKW, and ARKF—for a total value of $2,182,136. This acquisition continues a trend of ARK increasing its position in Roblox, which has been evident over the past week.
Another major transaction was the sale of 57,249 shares of Twilio Inc (NYSE:NYSE:), totaling $3,489,326. This move is part of a broader pattern of reducing exposure to Twilio, as ARK has consistently sold shares of the company in recent days.
ARK also took a significant position in 10X Genomics Inc (NASDAQ:TXG), buying 137,672 shares across ARKK and ARKG ETFs, with a dollar value of $5,004,376. This purchase is in line with ARK’s ongoing interest in the genomics sector, as evidenced by previous trades.
Additionally, ARK invested in Roku Inc (NASDAQ:), acquiring 33,464 shares through its ARKW ETF, amounting to $2,082,130. This purchase reflects ARK’s continued confidence in the streaming device company.
Sofi Technologies Inc (NASDAQ:SOFI) also saw a notable increase in ARK’s portfolio, with 166,792 shares bought through the ARKF ETF, valued at $1,257,611. This buy adds to ARK’s recent accumulations of SOFI shares.
Smaller yet strategic buys included Personalis Inc (NASDAQ:), with 10,193 shares added solely through the ARKG ETF for $13,760, and Twist Bioscience Corp (NASDAQ:), with 23,499 shares acquired across ARKK and ARKG ETFs, totaling $783,456.
Lastly, ARK’s interest in the biotech space was further underscored by the purchase of 43,182 shares of Verve Therapeutics Inc (NASDAQ:VERV) through the ARKG ETF, with an investment value of $376,115.
Investors following ARK’s trading activities should note the ongoing trends, such as the consistent buying of genomics-related stocks and the trimming of positions in certain tech companies, which may reflect ARK’s strategic adjustments to market conditions and future growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
